Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorigerlimab - MacroGenics

Next Previous
Drug Profile

Lorigerlimab - MacroGenics

Alternative Names: AEX1344; EXPASY; MGD-019; PD-1 x CTLA-4 bispecific DART molecule

Latest Information Update: 22 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gynaecological cancer; Ovarian cancer; Prostate cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 26 Aug 2025 MacroGenics completes a phase-I trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT05293496)
  • 22 Aug 2025 M.D. Anderson Cancer Center and MacroGenics plans a phase Ib/II trial for Colorectal Cancer (Metastatic disease, Combination therapy) in the US (PO) (NCT07137390)
  • 18 Jul 2025 M.D. Anderson Cancer Center in collaboration with MacroGenics plans a phase II trial for Colorectal cancer (Late-stage disease, Combination therapy, Second line therapy or greater) in USA (IV) (NCT07071961)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top